sNFL applicability as additional monitoring tool in Natalizumab Extended Interval Dosing regimen for RRMS patients

被引：0
|
作者：
Valentino, P. [1 ,2 ]
Malucchi, S. [3 ]
Martire, S. [4 ]
Bava, C. I. [1 ]
Capobianco, M. A. [2 ,5 ]
Bertolotto, A. [1 ,6 ]
机构：
[1] Neurosci Inst Cavalieri Ottolenghi NICO, Orbassano, Italy
[2] Univ Hosp San Luigi Gonzaga, CRESM Biobank, Orbassano, Italy
[3] Univ Hosp San Luigi Gonzaga, Neurol, Orbassano, Italy
[4] Univ Turin, Neurosci, Turin, Italy
[5] S Croce Carle Hosp, Neurol, Cuneo, Italy
[6] Koelliker Hosp, Turin, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1244
引用
收藏
页码：1006 / 1007
页数：2
相关论文
共 50 条
  • [21] Extended interval dosing of natalizumab: More evidence in support
    Toljan, Karlo
    Conway, Devon S.
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [22] Pharmacodynamics and pharmacokinetics of natalizumab administered at extended interval dosing
    Ryerson, L. Zhovtis
    Zuniga-Estrada, G.
    Jacob, A.
    Bacon, T.
    Pandey, K.
    Mohn, J.
    Kister, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 917 - 918
  • [23] Extended Interval Dosing of Natalizumab: A Single Center Experience
    Alderazi, Yazan J.
    Campagnolo, Denise
    Bomprezzi, Roberto
    NEUROLOGY, 2011, 76 (09) : A614 - A614
  • [24] Lymphocyte response in standard and extended interval dosing of natalizumab
    Rafee, S.
    Kennelly, L.
    Mcguigan, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 170 - 170
  • [25] Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen
    Hervas-Garcia, Jose Vicente
    Presas-Rodriguez, Silvia
    Crespo-Cuevas, Ane Miren
    Canento, Tamara
    Lozano-Sanchez, Manuel
    Massuet-Vilamajo, Anna
    Ramo-Tello, Cristina
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (05) : 399 - 402
  • [26] Modelling efficacy of natalizumab in patients who switch from standard interval dosing (SID) to extended interval dosing (EID)
    Chang, I.
    Muralidharan, K.
    Campbell, N.
    Ho, P. -R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 480 - 480
  • [27] Natalizumab: extended versus standard interval dosing in the real world
    Wagner, B.
    Richter, S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 880 - 881
  • [28] Extended interval dosing of natalizumab in MS; a New Zealand experience
    Chan, Calvin
    Siu, Ronald
    Mellsop, Nick
    Schepel, Jan
    NEUROLOGY, 2018, 90
  • [29] Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
    Foley, John F.
    Goelz, Susan
    Hoyt, Tamara
    Christensen, Angelene
    Metzger, Ryan R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 65 - 71
  • [30] Extended interval dosing and reduced dose of natalizumab in a Portuguese population
    Marques, P.
    Correia, I.
    Batista, S.
    Nunes, C.
    Macario, C.
    Campelo, I.
    Sousa, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 782 - 783
12345